CXCR4 and pancreatic neoplasm: A CXCR4 antagonist (BL-8040) combined with pembrolizumab and chemotherapy can increase the disease control rate of pancreatic cancer patients, promote the tumour infiltration of CD8+ T cells, and decrease the levels of myeloid-derived suppressor cells and circulating regulatory T cells [31].